69 search results for: type 2 inflammation

Beyond Itch: The Multifaceted Role of IL-4/IL-13 in the Pathogenesis of PN
Dermatology
Beyond Itch: The Multifaceted Role of IL-4/IL-13 in the Pathogenesis of PN
expert video

Professor Sarina Elmariah describes how IL-4 and IL-13, key drivers of type 2 inflammation, uniquely contribute to manifestations of prurigo nodularis beyond itch.

View more
The Role of IL-4 and IL-13 in CSU Pathogenesis
Type 2 Inflammation
The Role of IL-4 and IL-13 in CSU Pathogenesis
interactivity

Dive into the complex pathophysiology of chronic spontaneous urticaria (CSU), where mast cell degranulation drives the hallmark signs and symptoms. This interactive infographic elucidates how key type 2 cytokines, specifically IL-4 and IL-13, contribute to mast cell activation, immune cell trafficking into the skin, and neuronal sensitization in CSU, which ultimately leads to the release of mediators like histamine that cause wheals, angioedema, and itch.

View more
ADVENT On Air - Dermatology
Dermatology
ADVENT On Air | Expert Discussions in Dermatology
Podcast

Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.

View more
ADVENT at WCI
On Demand
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice

Join Professors Matthias Augustin and Sarina Elmariah for an engaging ADVENT symposium as they explore the pivotal role of type 2 inflammation in prurigo nodularis and chronic itch.

Immunological Drivers in CSU: Diverse Pathways to Mast Cell Activation
Dermatology
Immunological Drivers in CSU: Diverse Pathways to Mast Cell Activation
expert video

In this video from EADV 2025, Dr. Hawkes reviews the pathophysioogy of CSU with a focus on the role of type 2 inflammation

View more
Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction
Pulmonology
Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction
Infographic

Learn about the role of type 2 inflammation in the burden and pathophysiology of mucus plugging in severe asthma

View more
Clinical Manifestations Associated With Airway Remodeling in Asthma
Type 2 Inflammation
Clinical Manifestations Associated With Airway Remodeling in Asthma
expert video

Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.

View more
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients
Pulmonology
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients
Infographic

Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.

View more
Impact of Exacerbations in COPD
Type 2 Inflammation
Impact of Exacerbations in COPD
expert video

Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality

View more
Exacerbations Lead to Worsening Lung Function
Type 2 Inflammation
Exacerbations Lead to Worsening Lung Function
expert video

Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.

View more
Screen depicting a mucus plug in the airways
Pulmonology
A view into the Airway: The Pathophysiology and Clinical Relevance of Mucus Plugs in Asthma
videoanimation

Explore the role of type 2 inflammation in the production of mucus plugs in asthma and the effects these plugs can have on patients.

View more
EAACI <b>2</b>0<b>2</b>4 | On-Treatment Clinical Remission in Upper and Lower Airways: ​ Going Beyond Symptom Control​
Congress
31
May
2024
Congress
EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: ​ Going Beyond Symptom Control​

Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.